Neuronetics Reports Strong Transformation and Results for 2024
Neuronetics, Inc. (NASDAQ: STIM), a pivotal player in the healthcare technology landscape, has revealed its exciting fourth quarter and full year results for 2024, marking a significant year of transformation and growth. The company continues to lead the charge in neurohealth with its innovative therapies and strategies aimed at enhancing patient care.
Fourth Quarter Highlights
During the last quarter of 2024, Neuronetics posted remarkable highlights showcasing its commitment to both operational excellence and market expansion:
- Acquisition of Greenbrook TMS, executed on December 9, solidifying Neuronetics' market reach.
- Secured an additional $10 million in funding from Perceptive Advisors to bolster operations.
- Generated quarterly revenue of $22.5 million, reflecting an 11% increase compared to the previous year.
- Realized $3.8 million from U.S. NeuroStar Advanced Therapy System sales.
- Reported $12.9 million in U.S. treatment session revenue for the quarter.
- Incorporated Greenbrook's revenue of $4.4 million in the U.S. clinic segment after the acquisition.
Full Year Financial Performance
In 2024, Neuronetics demonstrated a strong business model with a full year revenue of $74.9 million, up by 5% year-over-year. The full year results reveal a robust U.S. treatment session revenue of $50.8 million and a successful FDA clearance for treating adolescents aged 15 and older. This regulatory approval is an important milestone, opening doors for better access to treatment for younger patients facing mental health challenges.
Recent Operational Improvements
Alongside strong financials, Neuronetics achieved several operational milestones that set the stage for future success:
- Executed a secondary offering of 9.2 million shares, generating around $18.9 million in net cash.
- Expected cost synergies from the Greenbrook acquisition are on track, with over $21 million already realized out of the targeted $22 million.
- Surpassed the milestone of treating over 195,000 patients globally, accumulating an impressive 7.1 million treatment sessions.
CEO Insights on Growth Strategy
Keith J. Sullivan, President and CEO of Neuronetics, shared insights on the company’s transformative journey. "2024 was a defining year as we've strategically reshaped our business and market position. The expansion of our Better Me Provider network and the acquisition of Greenbrook have established a unique TMS treatment platform. Early indicators suggest significant engagement among BMP participants, allowing them to treat more patients, boosting our revenue goals," stated Sullivan.
Sullivan elaborated on the company’s commitment to achieving double-digit revenue growth while aiming to be cash flow positive by the third quarter of 2025. With a clear goal of expanding mental health access, the leadership team is confident in Neuronetics' path forward.
Detailed Financial Overview
The financial outcomes for the quarter ending December 31, 2024, highlight significant growth, with total revenues reaching $22.5 million, an 11% rise compared to $20.3 million the previous year. The U.S. segment alone saw a growth of 9%, while international revenues skyrocketed by 93% compared to the same period in 2023. This growth stems primarily from the acquisition of Greenbrook.
However, Neuronetics experienced some decreases as well; meanwhile, gross margin for the fourth quarter stood at 66.2%, significantly lower compared to 77.6% a year earlier, mainly driven by Greenbrook’s integration.
2024 Annual Financial Results
For the full-year report, the financials indicate strong resilience despite challenges. Neuronetics reported an operating expense of $88.2 million, driven mainly by acquisition-related costs. Despite these expenses, Neuronetics remains committed to operational efficiency and long-term profitability.
Consolidated net loss for the year reached $(43.2) million, reflecting the investments in growth and integration of services. Notably, Adjusted EBITDA for the year was $(21.4) million.
Strategic Acquisition of Greenbrook TMS
The acquisition of Greenbrook TMS has been a game changer for Neuronetics. This union integrates Neuronetics' innovative NeuroStar technology with Greenbrook's established clinic operations. As the integration process progresses, the anticipated operational cost synergies of $22 million are seen as a clear pathway toward profitability.
Future Outlook
Looking forward, Neuronetics has set ambitious targets. For the first quarter of 2025, the company forecasts total worldwide revenue between $28 million and $30 million. For the entire year, expected revenue is projected between $145 million and $155 million, with operating expenses forecasted between $90 million and $98 million. Such projections demonstrate the confidence the leadership has in their capabilities and strategic direction.
Frequently Asked Questions
1. What were Neuronetics' revenue highlights for 2024?
Neuronetics reported a total revenue of $74.9 million for 2024, marking a 5% increase from the previous year.
2. How did the acquisition of Greenbrook TMS influence Neuronetics' performance?
The acquisition expanded Neuronetics' operational capacity, contributing significantly to revenue through increased treatment sessions and patient access.
3. What is Neuronetics' strategy for achieving profitability?
Neuronetics aims to achieve double-digit revenue growth while becoming cash flow positive by the third quarter of 2025.
4. What is the forecast for Neuronetics in 2025?
The company anticipates total revenue between $145 million and $155 million and expects to maintain operational synergies from the Greenbrook acquisition.
5. What is the significance of FDA clearance for Neuronetics?
The FDA clearance supports Neuronetics’ NeuroStar Advanced Therapy as a first-line treatment for adolescents, expanding its market reach and treatment options.
